English Polski

Wyszuk. zaawans.

Tom 23, Nr 1-2 (2021)
Artykuł poglądowy
Opublikowany online: 2022-12-30
Dodaj do koszyka: 49,00 PLN
Wyświetlenia strony 632
Wyświetlenia/pobrania artykułu 20
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Sulodeksyd a leki wenoaktywne — naczynioprotekcyjne zastosowania glikozaminoglikanów

Tomasz Urbanek1
DOI: 10.5603/ChP.2021.0008
Chirurgia Polska 2021;23(1-2):17-33.

Streszczenie

Działanie ochronne na śródbłonek naczyniowy, hamowanie reakcji zapalnej, hamowanie ekspresji metaloproteinaz oraz produkcji wolnych rodników tlenowych, jak również inne pluripotencjalne właściwości glikozaminoglikanów otwierają nowe perspektywy w leczeniu chorób układu żylnego oraz innych patologii naczyń obwodowych dotyczących zarówno tętnic, jak i mikrokrążenia. W pracy przedstawiono przegląd aktualnej wiedzy dotyczącej klinicznego wykorzystania naczynioprotekcyjnego wpływu glikozaminoglikanów w leczeniu chorób naczyń obwodowych, ze szczególnym uwzględnieniem przewlekłej choroby żył, jak również naczyniowych powikłań cukrzycy. Zgodnie z wykonanymi badaniami obejmującymi ocenę właściwości sulodeksydu na podstawie badań z zakresu nauk podstawowych, jak również zgodnie z obserwacjami dotyczącymi skuteczności klinicznej, działanie sulodeksydu wpisuje się w obecną definicję leków wenoaktywnych. Wykazany w badaniach klinicznych wpływ na redukcję objawów podmiotowych przewlekłej choroby żył, korzystny wpływ na redukcję obrzęku kończyn, jak również poprawa wyników leczenia owrzodzeń żylnych goleni u pacjentów stosujących glikozaminoglikany korespondują z wynikami badań laboratoryjnych dowodzących wielokierunkowego wpływu sulodeksydu na wiele procesów związanych z występowaniem przewlekłej choroby żylnej i jej powikłań. Naczynioprotekcyjny wpływ glikozaminoglikanów związany między innymi z wysokim powinowactwem do komórek śródbłonka naczyniowego oraz kontrolą homeostazy w naczyniach mikrokrążenia wykazano również w innych sytuacjach klinicznych, takich jak retinopatia czy też nefropatia cukrzycowa. Dostępne doniesienia omówione w pracy opisują także korzystny wpływ sulodeksydu na wydłużenie dystansu chromania u chorych z chorobą tętnic obwodowych, jak również sugerują wiele nowych potencjalnych obszarów, w których wykorzystanie glikozaminoglikanów może przynieść potencjalne korzyści kliniczne.

Słowa kluczowe: przewlekłe choroby żyłleczenie farmakologiczneleki wenoaktywneglikozaminoglikanysulodeksydleki naczynioprotekcyjnecukrzycapowikłania

Artykuł dostępny w formacie PDF

Dodaj do koszyka: 49,00 PLN

Posiadasz dostęp do tego artykułu?

Referencje

  1. Nicolaides A, Kakkos S, Baekgaard N, et al. Management of chronic venous disorders of the lower limbs. Guidelines According to Scientific Evidence. Part I. Int Angiol. 2018; 37(3): 181–254.
    CrossRefPubMed
  2. Fowkes FG, Evans CJ, Lee AJ. Prevalence and risk factors of chronic venous insufficiency. Angiology. 2001; 52(Suppl 1): S5–15.
    CrossRefPubMed
  3. Gohel MS, Davies AH. Pharmacological agents in the treatment of venous disease: an update of the available evidence. Curr Vasc Pharmacol. 2009; 7(3): 303–308.
    CrossRefPubMed
  4. Carpentier PH, Maricq HR, Biro C, et al. Prevalence, risk factors, and clinical patterns of chronic venous disorders of lower limbs: a population-based study in France. J Vasc Surg. 2004; 40(4): 650–659.
    CrossRefPubMed
  5. Jawien A. The influence of environmental factors in chronic venous insufficiency. Angiology. 2003; 54 Suppl 1: S19–S31.
    CrossRefPubMed
  6. Rabe E, Pannier-Fischer P, Bromen K, et al. Bonner Venenstudie der Deutschen Gesellschaft für . Epidemiologische Untersuchung zur Frage der Häufigkeit und Ausprägung von chronischen Venenkrankheiten in der städtischen und ländlichen Wohnbevölkerung. Phlebologie. 2003; 32: 1–14.
  7. Urbanek T, Dorobisz A, Gabriel M, et al. Assessment of public awareness in the field of epidemiology, prevention and treatment of chronic venous diseases in Poland. Phlebological Review. 2015; 2: 45–53.
    CrossRef
  8. Pitsch FV. CONSULT Program: interim results from the first 70 000 screened patients in 13 countries. Phlebolymphology. 2012; 19: 132–137.
  9. Howlader MH, Smith PD. Symptoms of chronic venous disease and association with systemic inflammatory markers. J Vasc Surg. 2003; 38(5): 950–954.
    CrossRefPubMed
  10. Lurie F, Passman M, Meisner M, et al. The 2020 update of the CEAP classification system and reporting standards. J Vasc Surg Venous Lymphat Disord. 2020; 8(3): 342–352.
    CrossRefPubMed
  11. Urbanek T, Skop B, Ziaja K, et al. Sapheno-femoral junction pathology: molecular mechanism of saphenous vein incompetence. Clin Appl Thromb Hemost. 2004; 10: 311–312.
    CrossRefPubMed
  12. Raffetto JD. Pathophysiology of Chronic Venous Disease and Venous Ulcers. Surg Clin North Am. 2018; 98(2): 337–347.
    CrossRefPubMed
  13. Kirsch D, Dienes HP, Küchle R, et al. Changes in the extracellular matrix of the vein wall--the cause of primary varicosis? Vasa. 2000; 29(3): 173–177.
    CrossRefPubMed
  14. Bergan JJ, Schmid-Schönbein GW, Smith PD, et al. Chronic venous disease. N Engl J Med. 2006; 355(5): 488–498.
    CrossRefPubMed
  15. Ortega MA, Fraile-Martínez O, García-Montero C, et al. Understanding Chronic Venous Disease: A Critical Overview of Its Pathophysiology and Medical Management. J Clin Med. 2021; 10(15).
    CrossRefPubMed
  16. Meissner MH, Eklof Bo, Smith PC, et al. Primary chronic venous disorders. J Vasc Surg. 2007; 46 Suppl S: 54S–67S.
    CrossRefPubMed
  17. Lim CS, Davies AH. Pathogenesis of primary varicose veins. Br J Surg. 2009; 96(11): 1231–1242.
    CrossRefPubMed
  18. Raffetto J, Khalil R. Matrix Metalloproteinases in Venous Tissue Remodeling and Varicose Vein Formation. Curr Vasc Pharmacol. 2008; 6(3): 158–172.
    CrossRefPubMed
  19. Nicolaides AN, Kakkos S, Eklof B, et al. Management of chronic venous disorders of the lower limbs: guidelines according to scientific evidence. Chapter 8: Venoactive Drugs. Int Angiol. 2014; 33: 126–139.
  20. Vein glossary red. M. Perrin, Institut la Conférence Hippocrate, Cedex, Francja 2018.
  21. Nicolaides A, Kakkos S, Eklof B, et al. Management of chronic venous disorders of the lower limbs - guidelines according to scientific evidence. Int Angiol. 2014; 33: 87–208.
    PubMed
  22. Monjotin N, Tenca G. Lymphotonic activity of Ruscus extract, hesperidin methyl chalcone and vitamin C in human lymphatic smooth muscle cells. Microvasc Res. 2022; 139: 104274.
    CrossRefPubMed
  23. Rauly-Lestienne I, Heusler P, Cussac D, et al. Contribution of muscarinic receptors to in vitro and in vivo effects of Ruscus extract. Microvasc Res. 2017; 114: 1–11.
    CrossRefPubMed
  24. Bergan JJ, Pascarella L, Schmid-Schönbein GW. Pathogenesis of primary chronic venous disease: Insights from animal models of venous hypertension. J Vasc Surg. 2008; 47(1): 183–192.
    CrossRefPubMed
  25. Hoppensteadt DA, Fareed J. Pharmacological profile of sulodexide. Int Angiol. 2014; 33: 229–35.
    PubMed
  26. Dou H, Song A, Jia S, et al. Heparinoids Danaparoid and Sulodexide as clinically used drugs. Prog Mol Biol Transl Sci. 2019; 163: 55–74.
    CrossRefPubMed
  27. Andreozzi GM. Sulodexide in the treatment of chronic venous disease. Am J Cardiovasc Drugs. 2012; 12(2): 73–81.
    CrossRefPubMed
  28. Broekhuizen LN, Lemkes BA, Mooij HL, et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia. 2010; 53(12): 2646–2655.
    CrossRefPubMed
  29. Mannello F, Ligi D, Raffetto JD. Glycosaminoglycan sulodexide modulates inflammatory pathways in chronic venous disease. Int Angiol. 2014; 33(3): 236–242.
    PubMed
  30. Masola V, Zaza G, Onisto M, et al. Glycosaminoglycans, proteoglycans and sulodexide and the endothelium: biological roles and pharmacological effects. Int Angiol. 2014; 33(3): 243–254.
    PubMed
  31. Zhang X, Sun D, Song J, et al. Endothelial cell dysfunction and glycocalyx – A vicious circle. Matrix Biology. 2018; 71-72: 421–431.
    CrossRefPubMed
  32. Ceriello A, Quatraro A, Marchi E, et al. Impaired fibrinolytic response to increased thrombin activation in type 1 diabetes mellitus: effects of the glycosaminoglycan sulodexide. Diabete Metab. 1993; 19(2): 225–229.
    PubMed
  33. Agrati AM, Mauro M, Savasta CA. double-blind, cross-over, placebo-controlled study of the profibrinolytic and antithrombotic effects of oral sulodexide. Adv Ther. 1992; 9: 147–155.
  34. Carroll BJ, Piazza G, Goldhaber SZ. Sulodexide in venous disease. J Thromb Haemost. 2019; 17(1): 31–38.
    CrossRefPubMed
  35. Barbanti M, Guizzardi S, Calanni F, et al. Antithrombotic and thrombolytic activity of sulodexide in rats. Int J Clin Lab Res. 1992; 22(3): 179–184.
    CrossRefPubMed
  36. Mauro M, Ferraro G, Palmieri GC. Profibrinolytic and antithrombotic effects of sulodexide oral administration: a double-blind, cross-over, placebo-controlled study. Curr Ther Res. 1992; 51: 342–350.
  37. Cerletti C, Rajtar G, Marchi E, et al. Interaction between glycosaminoglycans, platelets, and leukocytes. Semin Thromb Hemost. 1994; 20(3): 245–253.
    CrossRefPubMed
  38. Borawski J, Dubowski M, Pawlak K, et al. Effect of sulodexide on plasma transforming growth factor-beta1 in healthy volunteers. Clin Appl Thromb Hemost. 2010; 16(1): 60–65.
    CrossRefPubMed
  39. Coccheri S, Mannello F, Coccheri S, et al. Development and use of sulodexide in vascular diseases: implications for treatment. Drug Des Devel Ther. 2013; 8: 49–65.
    CrossRefPubMed
  40. Young E, Young E. The anti-inflammatory effects of heparin and related compounds. Thromb Res. 2008; 122(6): 743–752.
    CrossRefPubMed
  41. Urbanek T, Zbigniew K, Begier-Krasińska B, et al. Sulodexide suppresses inflammation in patients with chronic venous insufficiency. Int Angiol. 2015; 34(6): 589–596.
    PubMed
  42. Suminska-Jasinska K, Polubinska A, Ciszewicz M, et al. Sulodexide reduces senescence-related changes in human endothelial cells. Med Sci Monit. 2011; 17(4): CR222–CR226.
    CrossRefPubMed
  43. Mannello F, Ligi D, Canale M, et al. Sulodexide down-regulates the release of cytokines, chemokines, and leukocyte colony stimulating factors from human macrophages: role of glycosaminoglycans in inflammatory pathways of chronic venous disease. Curr Vasc Pharmacol. 2014; 12(1): 173–185.
    CrossRefPubMed
  44. Serra R, Gallelli L, Conti A, et al. The effects of sulodexide on both clinical and molecular parameters in patients with mixed arterial and venous ulcers of lower limbs. Drug Des Devel Ther. 2014; 8: 519–527.
    CrossRefPubMed
  45. Ligi D, Mosti G, Croce L, et al. Chronic venous disease – Part I: Inflammatory biomarkers in wound healing. Biochim Biophys Acta (BBA) - Molecular Basis of Disease. 2016; 1862(10): 1964–1974.
    CrossRef
  46. Raffetto JD, Yu W, Wang Xi, et al. Sulodexide Improves Contraction and Decreases Matrix Metalloproteinase-2 and -9 in Veins Under Prolonged Stretch. J Cardiovasc Pharmacol. 2020; 75(3): 211–221.
    CrossRefPubMed
  47. Kucukguven A, Khalil RA, Kucukguven A, et al. Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins. Curr Drug Targets. 2013; 14(3): 287–324.
    PubMed
  48. Saviano M, Maleti O, Liguori L, et al. Double-blind, double-dummy, randomized, multi-centre clinical assessment of the efficacy, tolerability and dose-effect relationship of sulodexide in chronic venous insufficiency. Curr Med Res Opin. 1993; 13(2): 96–108.
    CrossRefPubMed
  49. Bignamini AA, Matuška J, Bignamini AA, et al. Sulodexide for the Symptoms and Signs of Chronic Venous Disease: A Systematic Review and Meta-analysis. Adv Ther. 2020; 37(3): 1013–1033.
    CrossRefPubMed
  50. Cospite M, Ferrara F, Cospite V, et al. Sulodexide and the microcirculatory component in microphlebopathies. Curr Med Res Opin. 1992; 13(1): 56–60.
    CrossRefPubMed
  51. Elleuch N, Zidi H, Bellamine Z, et al. Sulodexide in Patients with Chronic Venous Disease of the Lower Limbs: Clinical Efficacy and Impact on Quality of Life. Advances in Therapy. 2016; 33(9): 1536–1549.
    CrossRefPubMed
  52. Guevara-Saldıvar MI, Garza-Ruiz AF, Guevara-Saldıvar MI, et al. Gonzales Ochoa A, Sulodexide for the management of chronic venous disease in clinical stages C3 and C4 Open observational study. Rev Mex Angiol. 2017; 17: 15–22.
  53. Bogachev VIu, Golovanova OV, Malysheva IN. [Efficacy of sulodexide in treatment of chronic venous insufficiency. Results of the ACCORD trial]. Angiol Sosud Khir. 2017; 23(3): 83–88.
    PubMed
  54. Coccheri S, Scondotto G, Agnelli G, et al. Venous arm of the SUAVIS (Sulodexide Arterial Venous Italian Study) Group. Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers. Thromb Haemost. 2002; 87(6): 947–952.
    PubMed
  55. Kucharzewski M, Franek A, Koziolek H. Treatment of venous leg ulcers with sulodexide. Phlebologie 2003; 32. ; 115: 120.
  56. Scondotto G, Aloisi D, Ferrari P, et al. Treatment of venous leg ulcers with sulodexide. Angiology. 1999; 50(11): 883–889.
    CrossRefPubMed
  57. Wu B, Lu J, Yang M, et al. Sulodexide for treating venous leg ulcers. Cochrane Database Syst Rev. 2016(6): CD010694.
    CrossRefPubMed
  58. Radbill B, Murphy B, LeRoith D. Rationale and strategies for early detection and management of diabetic kidney disease. Mayo Clin Proc. 2008; 83(12): 1373–1381.
    CrossRefPubMed
  59. Rudberg S, Osterby R. Diabetic glomerulopathy in young IDDM patients. Preventive and diagnostic aspects. Horm Res. 1998; 50 Suppl 1: 17–22.
    CrossRefPubMed
  60. Rossing P. Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history. Curr Diab Rep. 2006; 6(6): 479–483.
    CrossRefPubMed
  61. Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis. 2007; 49(1): 12–26.
    CrossRefPubMed
  62. Khosla N, Bakris G. Lessons learned from recent hypertension trials about kidney disease. Clin J Am Soc Nephrol. 2006; 1(2): 229–235.
    CrossRefPubMed
  63. Timothy C. Evans, Peter Capell Nefropatia cukrzycowa. Diabetologia Praktyczna. 2001; 2: 15–20.
  64. Yung S, Chau MKM, Zhang Q, et al. Sulodexide decreases albuminuria and regulates matrix protein accumulation in C57BL/6 mice with streptozotocin-induced type I diabetic nephropathy. PLoS One. 2013; 8(1): e54501.
    CrossRefPubMed
  65. Gambaro G, Cavazzana AO, Luzi P, et al. Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int. 1992; 42(2): 285–291.
    CrossRefPubMed
  66. Kristová V, Líšková S, Sotníková R, et al. Sulodexide improves endothelial dysfunction in streptozotocin-induced diabetes in rats. Physiol Res. 2008; 57(3): 491–494.
    CrossRefPubMed
  67. Liu YuN, Zhou J, Li T, et al. Sulodexide Protects Renal Tubular Epithelial Cells from Oxidative Stress-Induced Injury via Upregulating Klotho Expression at an Early Stage of Diabetic Kidney Disease. J Diabetes Res. 2017; 2017: 4989847.
    CrossRefPubMed
  68. Hało A. Budowa kłębuszka nerkowego. Pol J Pathol. 2011; 1(suplemement 1): s3–7.
  69. Shu J, Zeng Ly, Lin Ky, et al. [Renal protective effects of sulodexide in diabetic rats and its anti-oxidative mechanism]. Nan Fang Yi Ke Da Xue Xue Bao. 2009; 29(4): 778–780.
    PubMed
  70. Gabryel B, Jarząbek K, Machnik G, et al. Superoxide dismutase 1 and glutathione peroxidase 1 are involved in the protective effect of sulodexide on vascular endothelial cells exposed to oxygen-glucose deprivation. Microvasc Res. 2016; 103: 26–35.
    CrossRefPubMed
  71. Bignamini A, Chebil A, Gambaro G, et al. Sulodexide for Diabetic-Induced Disabilities: A Systematic Review and Meta-Analysis Adv Ther. 2021; 38: 1483–1513.
    CrossRefPubMed
  72. Cha JJ, Kang YS, Hyun YY, et al. Sulodexide improves renal function through reduction of vascular endothelial growth factor in type 2 diabetic rats. Life Sci. 2013; 92(23): 1118–1124.
    CrossRefPubMed
  73. Lewis EJ, Lewis JB, Greene T, et al. Collaborative Study Group. Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis. 2011; 58(5): 729–736.
    CrossRefPubMed
  74. Packham DK, Wolfe R, Reutens AT, et al. Collaborative Study Group. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol. 2012; 23(1): 123–130.
    CrossRefPubMed
  75. Heerspink HJL, Greene T, Tighiouart H, et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 2019;7:128–139.
  76. Rusin P, Majsterek I. Molekularne podstawy retinopatii cukrzycowej. Postepy Hig Med Dosw. 2007; 61: 786–796.
  77. Jewusiak – Rogulska M, Kocięcki J. Epidemiologia, klasyfikacja i nowoczesne metody leczenia retinopatii cukrzycowej. Nowiny Lekarskie. 2013; 82: 253–258.
  78. Tarr J, Kaul K, Chopra M, et al. Pathophysiology of Diabetic Retinopathy Hindawi Publishing Corporation ISRN Ophthalmology. ; 2013: ID.
  79. Song JH, Chin HS, Kwon OW, et al. DRESS Research Group. Effect of sulodexide in patients with non-proliferative diabetic retinopathy: diabetic retinopathy sulodexide study (DRESS). Graefes Arch Clin Exp Ophthalmol. 2015; 253: 829–37.
    CrossRefPubMed
  80. Rubbi F, Caramazza R, Boccia S. The effects of sulodexide on diabetic retinopathy. Minerva Cardioangiol. 2000; 48(Suppl 1): 81–2.
  81. Jo H, Jung S, Kang J, et al. Sulodexide inhibits retinal neovascularization in a mouse model of oxygen-induced retinopathy. BMB Rep. 2014; 47: 637–642.
    CrossRefPubMed
  82. Giurdanella G, Lazzara F, Caporarello N, et al. Sulodexide prevents activation of the PLA2/COX-2/VEGF inflammatory pathway in human retinal endothelial cells by blocking the effect of AGE/RAGE. Biochem Pharmacol. 2017; 142: 145–154.
    CrossRefPubMed
  83. Raffetto JD, Calanni F, Mattana P, et al. Sulodexide promotes arterial relaxation via endothelium-dependent nitric oxide-mediated pathway Biochem Pharmacol. 2019; 166: 347–356.
    CrossRefPubMed
  84. Radhakrishnamurthy B, Sharma C, Bhandaru RR, et al. Studies of chemical and biologic properties of a fraction of sulodexide, a heparin-like glycosaminoglycan. Atherosclerosis. 1986; 60(2): 141–149.
    CrossRefPubMed
  85. Lauver DA, Lucches B. Sulodexide: A Renewed Interest in This Glycosaminoglycan Cardiovascular Drug Reviews. 2006; 24: 214–226.
    CrossRefPubMed
  86. Połubińska A, Staniszewski R, Baum E, et al. Sulodexide modifies intravascular homeostasis what affects function of the endothelium. Adv Med Sci. 2013; 58(2): 304–310.
    CrossRefPubMed
  87. Park HY, Kang S, Kim GY, et al. Inhibition of neointimal proliferation of rat carotid artery by sulodexide. J Korean Med Sci. 1997; 12(3): 210–214.
    CrossRefPubMed
  88. Borawski J, Dubowski M, Pawlak K, et al. Sulodexide induces hepatocyte growth factor release in humans. Eur J Pharmacol. 2007; 558(1-3): 167–171.
    CrossRefPubMed
  89. Coccheri S, Scondotto G, Agnelli G, et al. Arterial Arm of the Suavis (Sulodexide Arterial Venous Italian Study) group. Sulodexide in the treatment of intermittent claudication. Results of a randomized, double-blind, multicentre, placebo-controlled study. Eur Heart J. 2002; 23(13): 1057–1065.
    CrossRefPubMed
  90. Moldovan C, Marc F. Farcas¸ D. Sulodexide treatment in patients with type 2 diabetes mellitus and intermittent claudication. Eur J Int Med. 2011; 22: S63.
  91. Bregovsky V, Zalesskaya A. The use of sulodexide inobliterating atherosclerosis of the lower extremities in patients with diabetes mellitus. Prob Endocrinol. 1998; 44: 16–8.
  92. Gaddi AV, Capello F, Gheorghe-Fronea OF, et al. Sulodexide improves pain-free walking distance in patients with lower extremity peripheral arterial disease: A systematic review and meta-analysis. JRSM Cardiovasc Dis. 2020; 9: 2048004020907002.
    CrossRefPubMed
  93. Andreozzi GM, Bignamini AA, Davì G, et al. Visonà A; SURVET Study Investigators. Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Circulation. 2015; 132: 1891–1897.
    CrossRefPubMed
  94. Luzzi R, Belcaro G, Dugall M, et al. The efficacy of sulodexide in the prevention of postthrombotic syndrome. Clin Appl Thromb Hemost. 2014; 20(6): 594–599.
    CrossRefPubMed
  95. Goldman MP, Sadick NS, Weiss RA. Cutaneous necrosis, telangiectatic matting, and hyperpigmentation following sclerotherapy. Etiology, prevention, and treatment. Dermatol Surg. 1995; 21(1): 19–29; quiz 31.
    CrossRefPubMed
  96. Gonzalez Ochoa AJ, Carrillo J, Manríquez D, et al. Reducing hyperpigmentation after sclerotherapy: A randomized clinical trial. J Vasc Surg Venous Lymphat Disord. 2021; 9(1): 154–162.
    CrossRefPubMed
  97. Szolnoky G. Sulodexide may be a real alternative to low molecular weight heparins in the prevention of COVID-19 induced vascular complications. Dermatol Ther. 2020; 33(6): e14437.
    CrossRefPubMed
  98. Magnani HN. Rationale for the Role of Heparin and Related GAG Antithrombotics in COVID-19 Infection. Clin Appl Thromb Hemost. 2021; 27: 1076029620977702.
    CrossRefPubMed
  99. Bikdeli B, Madhavan MV, Gupta A, et al. Global COVID-19 Thrombosis Collaborative Group. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thromb Haemost. 2020; 120(7): 1004–1024.
    CrossRefPubMed
  100. Gonzalez-Ochoa AJ, Raffetto JD, Hernández AG, et al. Sulodexide in the Treatment of Patients with Early Stages of COVID-19: A Randomized Controlled Trial. Thromb Haemost. 2021; 121(7): 944–954.
    CrossRefPubMed
  101. Condorelli M, Chiariello M, Dagianti A, et al. IPO-V2: A prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction. J Am Coll Cardiol. 1994; 23(1): 27–34.
    CrossRef
  102. Bikdeli B, Chatterjee S, Kirtane AJ, et al. Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials. Semin Thromb Hemost. 2020; 46(8): 908–918.
    CrossRefPubMed
  103. Gastaldi G, Pannier F, Roztočil K, et al. Chronic venous disease and diabetic microangiopathy: pathophysiology and commonalities. Int Angiol. 2021; 40(6): 457–469.
    CrossRefPubMed
  104. Shlyakova A, Strongin L, Kudykin M, et al. Clinical and pathogenetic features of lesions of the lower extremities in patients with type 2 diabetes mellitus and chronic venous insufficiency. Diabetes mellitus. 2016; 19(3): 212–220.
    CrossRef
  105. Matic P, Jolic S, Tanaskovic S, et al. Chronic Venous Disease and Comorbidities. Angiology. 2014; 66(6): 539–544.
    CrossRefPubMed
  106. Galanaud JP, Bertoletti L, Amitrano M, et al. RIETE registry investigators. Predictors of Post-Thrombotic Ulcer after Acute DVT: The RIETE Registry. Thromb Haemost. 2018; 118(2): 320–328.
    CrossRefPubMed
  107. Schiekofer S, Balletshofer B, Andrassy M, et al. Endothelial dysfunction in diabetes mellitus. Semin Thromb Hemost. 2000; 26(5): 503–511.
    CrossRefPubMed
  108. Wiernsperger NF, Bouskela E. Microcirculation in insulin resistance and diabetes: more than just a complication. Diabetes Metab. 2003; 29(4 Pt 2): 6S77–87.
    CrossRefPubMed
  109. Boyd RB, Burke JP, Atkin J, et al. Significance of capillary basement membrane changes in diabetes mellitus. J Am Podiatr Med Assoc. 1990; 80(6): 307–313.
    CrossRefPubMed
  110. Thiele K, Rau M, Hartmann NUK, et al. Diabetes Mellitus and Heart Failure. Am J Med. 2017; 130(6S): S40–S50.
    CrossRefPubMed
  111. Katorkin SE. [Significance of endothelial protection in treatment of patients with class c6 chronic venous disease and type 2 diabetes mellitus]. Angiol Sosud Khir. 2015; 21(3): 99–102, 104.
    PubMed
  112. Zakharova NO, Bulgakova SV, Katorkin SE, et al. [The treatment of elderly and senile patients with venous trophic ulcers and type 2 diabetes mellitus.]. Adv Gerontol. 2017; 30(6): 917–924.
    PubMed

Informacje o plikach cookie

Niezbędne pliki cookie

Zawsze aktywne

Te pliki cookie są niezbędne do prawidłowego wyświetlania i działania strony internetowej. Zablokowanie ich może spowodować nieprawidłowe działanie strony.

Analityczne pliki cookie

W ramach naszej strony internetowej korzystamy z narzędzi analitycznych, takich jak Google Analytics, które umożliwiają nam weryfikację ruchu na stronie internetowej. Narzędzia te mogą wymagać użycia plików cookie.

Społecznościowe pliki cookie

Są to pliki cookie powiązane z portalami społecznościowymi, z których korzystamy. Zaakceptowanie ich pozwoli na powiązanie Twojej wizyty na stronie z naszymi profilami w mediach społecznościowych.

Marketingowe pliki cookie

Są to pliki cookie odpowiedzialne za prowadzenie działań reklamowych i marketingowych - zgoda na ich wykorzystanie pozwoli nam kierować do Ciebie reklamy, bazujące na podstawie Twoich wcześniejszych aktywności w ramach naszej stronie internetowej.

Chirurgia Polska

O Via Medica Reklama
Księgarnia (Ikamed) TVMed
Aktualności
Copyright © 2023 Via Medica Regulations Cookie policy Privacy policy Legal Notice